SCHEDULE: Logos Global Discloses 5.6% Stake in Avalo Therapeutics

Logos Global Management LP and its affiliates have reported a 5.6% beneficial ownership stake in Avalo Therapeutics, Inc., comprising common stock and options.

Summary

• Logos Global Management LP, along with its affiliated entities Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, collectively reported a 5.6% beneficial ownership stake in Avalo Therapeutics, Inc.
• The aggregate amount beneficially owned by these reporting persons is 1,285,000 shares of Avalo Therapeutics' Common Stock.
• This ownership comprises 285,000 shares of Common Stock and options to acquire an additional 1,000,000 shares of Common Stock.
• The 5.6% ownership percentage is calculated based on 22,788,452 shares of Common Stock outstanding as of March 18, 2026, as reported in Avalo Therapeutics' Form 10-K for the fiscal year ended December 31, 2025.
• All reporting persons share both voting and dispositive power over the 1,285,000 beneficially owned shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Avalo Therapeutics, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the disclosure of a significant institutional stake, which can be interpreted as a vote of confidence, although it is a passive investment.

Positives

• Increased institutional ownership by Logos Global Management LP and its affiliates, potentially signaling investor interest in Avalo Therapeutics.
• The stake includes options to acquire 1,000,000 shares, indicating a potential future commitment or belief in the company's upside.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership positions, which can sometimes precede increased market attention or strategic shifts, particularly in the biotechnology sector where Avalo Therapeutics operates. Such disclosures are a routine part of market transparency.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, potentially signaling confidence from a notable investment firm.

Key Dates

Keywords

Avalo Therapeutics, Logos Global Management, Institutional Ownership, Schedule 13G, Common Stock, Biotechnology, Investment, Options